May 2026 in “Meditsinskiy sovet = Medical Council” This review outlines the benefits of menopausal hormone therapy for improving skin properties in peri- and postmenopausal women, emphasizing that interdisciplinary management enhances quality of life but noting the aesthetic improvements are secondary outcomes.
April 2026 in “International Journal of Drug Delivery Technology” This study among college-going girls in Tamil Nadu found that the average age of menarche was 12.84 years, with associations to factors like family history, lifestyle, and residential settings, highlighting a generational decline in menarche age and the need for further public health research.
March 2026 in “Archives of Dermatological Research” People with androgenetic alopecia may have a higher genetic risk for cardiovascular diseases.
March 2026 in “Ukrains kyi Visnyk Psykhonevrolohii” In this study, female patients with mixed alopecia reported significantly lower quality of life compared to those with metabolic alopecia, with poorer psychological well-being and personal fulfillment, linked closely to mental maladaptation severity, suggesting a biopsychosocial treatment approach.
January 2026 in “Clinics in Dermatology” This discussion examines the aesthetic symptoms of perimenopause, such as hot flashes and skin changes, and reviews management options like hormone replacement therapy and topical cosmetics, emphasizing the importance of consistency in treatment to maintain results.
January 2026 in “Journal of Cosmetic Dermatology” This study reviewed evidence suggesting that the loss of dermal white adipose tissue (dWAT) during menopause may be linked to decreased estrogen levels, potentially affecting skin health, and discussed non-hormonal treatments, like magnolol, that might help restore dWAT and improve menopausal skin changes.
In this chapter, the authors discuss how the decline in estrogen during menopause affects skin health, detailing changes like dryness, thinning, and increased sensitivity, and suggest management strategies such as lifestyle adjustments and hormone replacement therapy to address these issues.
January 2026 in “Industrial Psychiatry Journal” This study highlights the significant psychiatric effects associated with dengue fever, noting diverse psychological reactions that occur before, during, and after infection, such as anxiety, depression, and even psychosis, and underscores the need for integrated mental health strategies within public health systems for dengue.
This study discusses the potential of phytochemicals, such as isoflavones and polyphenols, to manage PCOS symptoms by improving insulin resistance, regulating hormones, and reducing cyst size, highlighting their promise as alternative treatments given the limitations of current pharmacological options.
November 2025 in “Frontiers in Immunology” In this study, researchers found significant links between specific metabolic reprogramming-related genes and alopecia areata risk, highlighting increased SQSTM1 expression in affected hair follicles compared to healthy ones.
November 2025 in “Journal of Complementary and Alternative Medical Research” In this study, researchers used molecular docking analysis to explore the potential of spearmint's phytochemicals in managing PCOS, identifying oleanolic acid as having the best binding affinity with proteins associated with the condition. However, these results are computational and require further laboratory experiments for validation.
November 2025 in “DOAJ (DOAJ: Directory of Open Access Journals)” This study identified elevated CD25 on secreting CD4 regulatory T cells as a genetic risk factor for androgenetic alopecia, with certain plasma proteins acting as mediators in this causal relationship.
November 2025 in “Asian Journal of Medical Sciences” In this study of women with PCOS in a rural setting, researchers observed no significant differences in hormonal or metabolic profiles based on age at menarche, but early menarche was associated with higher hirsutism, suggesting it could serve as an indicator of hyperandrogenism risk.
In this study, only a small percentage of women with polycystic ovary syndrome reported using holistic management strategies, highlighting a need for increased focus on comprehensive approaches to managing the condition.
October 2025 in “Skin Research and Technology” The article's findings are unreliable and have been retracted.
September 2025 in “Clinics and Practice” This study found that six-month supplementation with fish-derived collagen peptides, calcium, and vitamin D3 improved skin hydration and elasticity and reduced hair loss in menopausal women, with collagen playing a dominant role in enhancing skin elasticity.
August 2025 in “Libyan Medical Journal” This study found that patients with vitiligo or alopecia areata have higher levels of anxiety and depression compared to healthy individuals, though no significant differences were observed between the two patient groups, highlighting the psychological impact of these dermatological conditions.
August 2025 in “Obstetrics and gynecology.” This article reviews the management of polycystic ovarian syndrome, highlighting lifestyle modification and individualized pharmacological treatment strategies, and reports no new clinical results.
July 2025 in “Journal of Clinical Medicine” This study found that women with polycystic ovary syndrome reported significantly higher levels of psychological symptoms, such as depression and anxiety, compared to healthy controls, with higher stress and lower self-efficacy linked to increased symptom severity.
June 2025 in “Skin Research and Technology” The study's findings on omega-6 and hair loss are unreliable.
The research examined Crown-X, a novel formulation containing Menstrual Stem Cells, and found that it promoted significant proliferation of human dermal papilla cells, suggesting its potential as a non-invasive treatment for male pattern baldness. Future clinical trials are necessary to confirm its efficacy.
May 2025 in “Annals of surgical case reports & images.” Certain gut bacteria may protect against hair loss, while others may increase the risk.
April 2025 in “International Journal of Dermatology and Venereology” This study found a significant causal relationship between androgenetic alopecia and schizophrenia, but no causal association between schizophrenia and androgenetic alopecia.
November 2024 in “The Journal of Dermatology” This study found that atopic diseases such as atopic dermatitis, asthma, and allergic rhinitis increase the risk of developing alopecia areata, suggesting a significant role for T cell-related inflammation in the condition's mechanism.
This study identified four genes related to alopecia areata: GIMAP6 and ALOX15 as risk factors, and GALNT6 and HEG1 as protective factors, noting significant validation differences in GALNT6 and HEG1.
July 2024 in “Jurnal Pengabdian Masyarakat Putri Hijau” This study involved educating Dewantara Husada Health Vocational High School students about using meniran leaf extract in pomade formulations as a hair growth stimulant, demonstrating high engagement and interest in the topic.
July 2024 in “Clinical Cosmetic and Investigational Dermatology” Certain immune cells are linked to non-scarring hair loss, suggesting potential for immune-targeted treatments.
May 2024 in “Jurnal Penelitian Farmasi dan Herbal” In this experimental study on rabbits, the authors concluded that a pomade containing 10% meniran leaf extract was an effective hair growth stimulant and could compete with a positive control, fulfilling the required pomade characteristics.
March 2024 in “Ukraïnsʹkij vìsnik psihonevrologìï” This study found that among women with diffuse alopecia, 47.7% exhibited psychopathological symptoms, with mixed alopecia patients showing more severe manifestations compared to those with metabolic alopecia, suggesting the need for personalized management strategies.
January 2024 in “Scientific reports” This study found that undiluted mint leaf extract effectively inhibited multidrug-resistant Staphylococcus aureus and killed Culex pipiens larvae, suggesting its potential as a biocontrol strategy around hospitals.